Concrete is an album by Fear Factory, released on July 30, 2002. It contains songs recorded in 1991 which were intended to be the band's first release, half of which were re-recorded a year later and released on their debut album Soul of a New Machine.
Although released in 2002, Concrete was originally recorded in 1991 in Blackie Lawless's studios. It was intended to be Fear Factory's first release, but the band wasn't happy with the record deal they were in, so they left their producer, Ross Robinson.
When they were taken to court, Robinson won the rights to the album, and the band retained the rights to the songs. Fear Factory would later re-record eight of the songs for their 1992 debut, Soul of a New Machine, recording under the name "Factoría de Miedo" (Spanish for "Fear Factory") to hide from their label. Robinson would use the album to promote himself, eventually leading to him producing Korn, which would make him the most sought-after nu metal producer of the 1990s. After the band's breakup in 2002, Roadrunner Records released the album to help meet unfulfilled contractual obligations.
Eight of the songs on Concrete were re-recorded in 1992 and released on Soul of a New Machine: "Big God/Raped Souls", "Arise Above Oppression", "Crisis", "Escape Confusion", "Dragged Down by the Weight of Existence" (re-recorded as "W.O.E"), "Desecrate", "Suffer Age", and "Self Immolation". "Concrete" was later renamed as "Concreto" and re-recorded as a b-side for the "Dog Day Sunrise" single, and later appeared as a bonus track for the digipak release of Obsolete.
"Piss Christ" is not the same song as "Pisschrist", which appears on Demanufacture. "Ulceration" is named after the band's original name. "Sangre de Niños" ("Children's Blood" in Spanish) was originally featured on one of the Cry Now, Cry Later 7" compilations released under the "Factoría de Miedo" moniker. "Soulwound" (a bonus track for Obsolete) is not a renamed and re-recorded version of "Soulwomb". The opening guitar riff in "Echoes of Innocence" was used as a synthesized motif in "A Therapy for Pain", the final track on Demanufacture. The title also appears in that song as a lyric.
|1.||"Big God/Raped Souls"||Bell, Cazares, Herrera||2:36|
|2.||"Arise Above Oppression"||Bell, Cazares, Herrera||1:57|
|3.||"Concrete"||Bell, Cazares, Herrera||2:28|
|4.||"Crisis"||Bell, Cazares, Herrera||3:33|
|5.||"Escape Confusion"||Cazares, Herrera||3:37|
|6.||"Sangre de Niños"||Bell, Cazares, Herrera||2:03|
|7.||"Soulwomb"||Bell, Cazares, Herrera||2:35|
|8.||"Echoes of Innocence"||Bell, Cazares, Herrera||3:04|
|9.||"Dragged Down by the Weight of Existence"||Bell, Cazares, Herrera||2:42|
|10.||"Deception"||Bell, Cazares, Herrera||0:29|
|11.||"Desecrate"||Bell, Cazares, Herrera||2:37|
|12.||"Suffer Age"||Cazares, Herrera||3:45|
|13.||"Anxiety"||Bell, Cazares, Herrera||1:39|
|14.||"Self Immolation"||Bell, Cazares, Herrera||2:34|
|15.||"Piss Christ"||Bell, Cazares, Herrera||2:41|
|16.||"Ulceration"||Bell, Cazares, Herrera||2:45|
Writing, performance and production credits are adapted from the album liner notes.
- Dave Gibney − spoken word on "Big God", vocals on "Raped Souls"
- Blackie Lawless's Fort Apache Studio, Los Angeles, CA, USA – engineering, mixing
- Oasis Mastering, Los Angeles, CA, USA – mastering
1. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387–402.[PubMed]
2. EACS guidelines. 2012. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf . Accessed 24 June 2013.
3. Antiretroviral therapy for HIV infection in adults and adolescents. 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf . Accessed 24 June 2013. [PubMed]
4. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.[PubMed]
5. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535–40.[PubMed]
6. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257–63.[PubMed]
7. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165–73.[PubMed]
8. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329–36.[PubMed]
9. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53:62–9.[PubMed]
10. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–96.[PubMed]
11. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther. 2009;14:543–9.[PMC free article][PubMed]
12. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867–75.[PMC free article][PubMed]
13. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–78.[PubMed]
14. Campbell LJ, Dew T, Salota R, et al. Urinary albumin and retinol-binding protein as markers of glomerular and tubular dysfunction in HIV infected patients. 12th European AIDS Conference/EACS; 11–14 November 2009; Cologne, Germany.
15. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25:1603–9.[PMC free article][PubMed]
16. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331–3.[PubMed]
17. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24:415–8.[PubMed]
18. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature. J Infect. 2005;51:E61–5.[PubMed]
19. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387–94.[PubMed]
20. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78–81.[PubMed]
21. Yoshino M, Yagura H, Kushida H, et al. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation. J Infect Chemother. 2012;18:169–74.[PubMed]
22. Bonjoch A, Echeverria P, Perez-Alvarez N, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res. 2012;96:65–9.[PubMed]
23. Campbell LJ, Hamzah L, Post FA. Is tenofovir-related renal toxicity incompletely reversible? J Acquir Immune Defic Syndr. 2011;56:e95.[PubMed]
24. Fafin C, Pugliese P, Durant J, et al. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m. Nephron Clin Pract. 2012;120:c205–14.[PubMed]
25. Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26:1907–15.[PMC free article][PubMed]
26. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med. 2004;5:115–24.[PubMed]
27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.[PMC free article][PubMed]
28. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant. 2011;27:2291–7.[PubMed]
29. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2) Pharm Res. 2007;24:811–5.[PubMed]
30. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001;299:567–74.[PubMed]
31. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469–87.[PMC free article][PubMed]
32. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108–16.[PubMed]
33. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171–7.[PubMed]
34. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278–83.[PubMed]
35. Fux C, Opravil M, Cavassini M, et al. Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study. 16th Conference on Retroviruses and Opportunistic Infections; 8–11 February 2009; Montreal, Canada,.
36. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS. 2012;26:567–75.[PubMed]
37. Dazo C, Fahey P, Puls RL, et al. Small but significant and non-progressive decline in glomerular filtration rate is observed in therapy naïve HIV-positive subjects commencing ritonavir-boosted atazanavir (r/ATV), compared to either efavirenz (EFV) or zidovudine/abacavir (ZDV/ABC) all with tenofovir (TDF)/emtricitabine (FTC) after 48 weeks, a randomised controlled study. 18th Conference on Retroviruses and Opportunistic Infections; 2011. Boston, 27 Feb–2 March.
38. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716–23.[PMC free article][PubMed]
39. Biesecker G, Karimi S, Desjardins J, et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res. 2003;58:217–25.[PubMed]
40. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505.[PubMed]
41. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56:567–75.[PubMed]
42. Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 2011;25:2149–55.[PubMed]
43. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–7.[PubMed]